These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 6104624)

  • 1. [Structure, levels and deficiencies regarding the abilities of schizophrenics (author's transl)].
    Schelling U
    Fortschr Neurol Psychiatr Grenzgeb; 1980 May; 48(5):249-66. PubMed ID: 6104624
    [No Abstract]   [Full Text] [Related]  

  • 2. [The therapy of first time hospitalized schizophrenics (author's transl)].
    Hartmann W; Müller P
    Fortschr Neurol Psychiatr Grenzgeb; 1974 Dec; 42(12):601-14. PubMed ID: 4498818
    [No Abstract]   [Full Text] [Related]  

  • 3. [A critical study of the influence of negative symptoms on the therapeutic response in schizophrenia].
    Acuña MJ; Martín J; Noval D; Blanco M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):209-13. PubMed ID: 9807853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics.
    Spohn HE; Coyne L
    Brain Cogn; 1993 Sep; 23(1):28-39. PubMed ID: 8105820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimodality and lateral asymmetry of skin conductance orienting activity in schizophrenics: replication and evidence of lateral asymmetry in patients with depression and disorders of personality.
    Gruzelier J; Venables P
    Biol Psychiatry; 1974 Feb; 8(1):55-73. PubMed ID: 4150082
    [No Abstract]   [Full Text] [Related]  

  • 6. [On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics (author's transl)].
    Náhunek K; Svestka J; Cesková E
    Cesk Psychiatr; 1981 Feb; 77(1):25-30. PubMed ID: 6113897
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
    Kathmann N; Wagner M; Rendtorff N; Engel RR
    Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of clinical characteristics and antipsychotic medication prescribing practices of first-episode schizophrenia in Israel: a naturalistic prospective study.
    Strous RD; Bar F; Keret N; Lapidus R; Kosov N; Chelben J; Kotler M
    Isr J Psychiatry Relat Sci; 2006; 43(1):2-9. PubMed ID: 16910378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic medication and length of stay at a psychiatric maximum-security unit in Norway (1987-2000).
    Renkel S; Rasmussen K
    Nord J Psychiatry; 2006; 60(2):132-6. PubMed ID: 16635932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aging of schizophrenics. Psycho-clinical study based on the Rorschach and Szondi tests].
    Melon J; Lebas A; Lieutenant L
    Acta Psychiatr Belg; 1973 Jan; 73(1):155-84. PubMed ID: 4599574
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical trial of oxyprothepin decanoate (author's transl)].
    Kabes J; Balon R; Hanzlícek L; Skovajsová M; Kozáková H
    Cesk Psychiatr; 1980 Feb; 76(1):16-25. PubMed ID: 6103755
    [No Abstract]   [Full Text] [Related]  

  • 12. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prophylactic efficacy of long-acting vs. short-acting neuroleptics in schizophrenic out-patients (author's transl)].
    Tegeler J; Lehmann E; Stockschlaeder M
    Nervenarzt; 1980 Nov; 51(11):654-61. PubMed ID: 6109262
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors related to the severity of tardive dyskinesia.
    Wade JB; Hart RP; Dougherty LM
    Brain Cogn; 1993 Sep; 23(1):71-80. PubMed ID: 8105823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients with schizophrenia successive to childhood attention deficit hyperactivity disorder (ADHD).
    Elman I; Sigler M; Kronenberg J; Lindenmayer JP; Doron A; Mendlovic S; Gaoni B
    Isr J Psychiatry Relat Sci; 1998; 35(4):280-6. PubMed ID: 9988985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy.
    Saletu B; Küfferle B; Grünberger J; Anderer P
    Pharmacopsychiatry; 1986 Nov; 19(6):434-7. PubMed ID: 2879297
    [No Abstract]   [Full Text] [Related]  

  • 17. [Performance in attention tests in chronic schizophrenics treated with Mepiprazol (author's transl)].
    Gonçalves N; Fieguth G
    Pharmakopsychiatr Neuropsychopharmakol; 1973 May; 6(3):167-77. PubMed ID: 4603734
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic reassessment and treatment response in schizophrenia.
    Honer WG; Smith GN; MacEwan GW; Kopala L; Altman S; Yorkston N; Ehmann TS; Smith A; Lang M
    J Clin Psychiatry; 1994 Dec; 55(12):528-32. PubMed ID: 7814346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Catamnestic study of schizophrenics treated with insulin coma therapy and schizophrenics treated with neuroleptics].
    Vachutka J
    Cesk Psychiatr; 1983 Dec; 79(6):392-5. PubMed ID: 6140083
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent psychostimulant use in hospitalized schizophrenics.
    Richard ML; Liskow BI; Perry PJ
    J Clin Psychiatry; 1985 Mar; 46(3):79-83. PubMed ID: 2857708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.